LS-SCLC
Dec 13, 2024
AstraZeneca’s IMFINZI Archives Another Milestone — Becomes the First Immunotherapy for Limited-Stage Small-cell Lung Cancer
AstraZeneca has secured another approval for its cancer blockbuster IMFINZI (durvalumab), as the FDA has approved the PD-L1 inhibitor for patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent chemotherapy and radiation. This approval makes IMFINZI the ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
